Hirota Y, Matsumoto I, Aso T, Kondou S, Ikematsu W, Hino H, Nishiura S, Yoneda K, Shiraishi T
Department of Internal Medicine, Matsuyama Red Cross Hospital, Japan.
Jpn J Med. 1990 Mar-Apr;29(2):203-7. doi: 10.2169/internalmedicine1962.29.203.
Acute myeloblastic leukemia (AML) was diagnosed in a 54-year-old male, a chronic hepatitis B surface antigen (HBsAg) carrier, in June, 1983. Prompt remission was achieved, and maintenance and intensification chemotherapy were given for five years. He was readmitted in March, 1988 because of a mass in the liver and was diagnosed as having hepatocellular carcinoma (HCC). Curative right segmentectomy was performed in May, 1988. In December, 1988, transitional cell carcinoma of the bladder was discovered, and resected transurethrally. These secondary neoplasms, HCC and bladder cancer, were thought to be associated with the long-term chemotherapy given for the AML.
1983年6月,一名54岁的男性被诊断为急性髓细胞白血病(AML),他是一名慢性乙型肝炎表面抗原(HBsAg)携带者。患者迅速达到缓解,并接受了为期五年的维持和强化化疗。1988年3月,他因肝脏肿块再次入院,被诊断为肝细胞癌(HCC)。1988年5月进行了根治性右半肝切除术。1988年12月,发现膀胱移行细胞癌,并经尿道切除。这些继发性肿瘤,即肝癌和膀胱癌,被认为与AML的长期化疗有关。